Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

uliledlimab (TJD5)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

I-Mab, PT Kalbe Farma, Tracon Pharma

Drug class:

CD73 inhibitor

Related drugs:

CD73 expression	Solid Tumor	CD73 expression	Solid Tumor	atezolizumab + TJD5 Sensitive: C3 – Early Trials atezolizumab + TJD5 Sensitive : C3	atezolizumab + TJD5 Sensitive: C3 – Early Trials atezolizumab + TJD5 Sensitive : C3
ALK wild-type + NT5E overexpression + PD-L1 expression	Non Small Cell Lung Cancer	ALK wild-type + NT5E overexpression + PD-L1 expression	Non Small Cell Lung Cancer	toripalimab-tpzi + TJD5 Sensitive: C3 – Early Trials toripalimab-tpzi + TJD5 Sensitive : C3	toripalimab-tpzi + TJD5 Sensitive: C3 – Early Trials toripalimab-tpzi + TJD5 Sensitive : C3
EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression	Non Small Cell Lung Cancer	EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression	Non Small Cell Lung Cancer	toripalimab-tpzi + TJD5 Sensitive: C3 – Early Trials toripalimab-tpzi + TJD5 Sensitive : C3	toripalimab-tpzi + TJD5 Sensitive: C3 – Early Trials toripalimab-tpzi + TJD5 Sensitive : C3